このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

直腸がんの治療を受けている患者の周術期転帰に対する術前の運動と栄養の最適化の影響: PROPEL 試験

2026年9月28日 更新者:Jeffrey A. Meyerhardt, MD、Dana-Farber Cancer Institute

The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.

The names of the groups in this research study are:

  • Group A: Prehabilitation program
  • Group B: Usual Care

調査の概要

詳細な説明

This is a non-blinded, randomized control trial to determine the feasibility of a hybrid-model, prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant therapy (chemotherapy and/or radiation) before surgical resection. Investigators hope that prehabilitation will result in improved outcomes after surgery.

Participants will be randomized into one of the study groups: Group A: prehabilitation program, or Group B: usual care. Randomization means that a participant is placed into a group by chance.

The research study procedures include screening for eligibility, in-clinic visits, physical exams, exercise training, blood tests, and questionnaires.

It is expected that about 40 participants will take part in this research study.

研究の種類

介入

入学 (推定)

40

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • 募集
        • Brigham and Women's Hospital
        • コンタクト:
        • 主任研究者:
          • Joel Goldberg, MD
      • Boston、Massachusetts、アメリカ、02115
        • 募集
        • Dana-Farber Cancer Institute
        • 主任研究者:
          • Jeffrey Meyerhardt, MD
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age greater than or equal to 18 years at time of enrollment.
  • English-Speaking.
  • Diagnosis of clinical stage II-III rectal cancer.
  • Planned, ongoing or just completed neoadjuvant treatment, including either 1) chemoradiation, 2) total neoadjuvant therapy (TNT), or 3) chemotherapy only; and anticipated surgical resection to follow.
  • Able to understand the study procedures, agree to participate in the study program, and voluntarily provide informed consent.

Exclusion Criteria:

  • Distant metastatic disease known at the time of diagnosis.
  • Functional incapacity (i.e., incapable of performing exercise testing).
  • Comorbid conditions or cognitive/physical impairments that contraindicate exercise.
  • Currently undergoing treatment for a secondary primary tumor, in addition to primary rectal cancer.
  • Currently enrolled in a separate clinical trial that would prohibit them from performing the tasks instructed in this trial.
  • Currently participating in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described intervention, where additional exercise done regularly will contaminate the intervention effects.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group A: Prehabilitation Program

Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:

  • In-clinic baseline visit with assessments
  • Virtual exercise sessions 3 days per week for 4 weeks.
  • IMN supplementation and daily multivitamin starting at 4 weeks of the preoperative phase.
  • Resection surgery per standard of care
  • In-clinic 30 day postoperative visit.

A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.

介入なし:Group B: Usual Care

Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:

  • In-clinic baseline visit with assessments
  • Resection surgery per standard of care
  • In-clinic 30 day postoperative visit
  • After completion of the study period, participants will be offered exercise equipment with an exercise instruction booklet.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Enrollment Rate
時間枠:Baseline

The proportion of eligible individuals that are enrolled to the study. Feasibility of the intervention is defined as an enrollment rate of greater than 10% of approached, eligible participants.

Baseline

二次結果の測定

結果測定
メジャーの説明
時間枠
Adherence Rate to the Prehabilitation Program
時間枠:At post-intervention (approximately Week 4)

The number of intervention assessments completed by participants in Group A. Feasibility of the intervention is defined as at least 50% of participants adhering to at least 50% of the prescribed assessments of the prehabilitation program.

At post-intervention (approximately Week 4)
Completion Rate of Physical Function Testing (Group A)
時間枠:At post-intervention (approximately Week 4)

Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants.

At post-intervention (approximately Week 4)
Completion Rate of Physical Function Testing (Group B)
時間枠:At post-intervention (approximately Week 4)

Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants.

At post-intervention (approximately Week 4)
Completion Rate of Questionnaire Assessments
時間枠:At baseline and the postoperative visit (approximately Week 9)

Defined as the number of questionnaires completed by all participants.

At baseline and the postoperative visit (approximately Week 9)
Participant Fall Rate (Group A)
時間枠:At post-intervention (approximately Week 4)

Defined as the number of falls attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Participant Fall Rate (Group B)
時間枠:At post-intervention (approximately Week 4)

Defined as the number of falls attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Hospitalization (Group A)
時間枠:At post-intervention (approximately Week 4)

Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Hospitalization (Group B)
時間枠:At post-intervention (approximately Week 4)

Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Musculoskeletal Injury (Group A)
時間枠:At post-intervention (approximately Week 4)

Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Musculoskeletal Injury (Group B)
時間枠:At post-intervention (approximately Week 4)

Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Change in Resting Blood Pressure from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

Assessed by resting blood pressure. The average systolic blood pressure (of two measurements from each arm) will be recorded.

From baseline to post-operative visit (approximately week 9)
Change in Cardiorespiratory Fitness from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

Assessed by VO2peak by a graded maximal (or submaximal if equipment is unavailable) cycle exercise stress test. VO2peak is defined as the highest values of oxygen uptake averaged among every 30-second interval during the test. VO2peak will be reported in both relative (ml·kg-1·min-1) and absolute (L/min) terms.

From baseline to post-operative visit (approximately week 9)
Change in Short Physical Performance Battery (SPPB) Score from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

Assessed by the Short Physical Performance Battery (SPPB) which is comprised of three sections: 1) balance with feet together, semi tandem, and full tandem is held for up to 10 seconds with no support and measure in seconds. Scores are summed for the measure of balance for a range of 0 to 30 seconds; 2) usual gait speed over four meters is timed (seconds); and 3) chair stand where the time(s) to complete five chair sit-to-stands is recorded. Each of the three performance measures is assigned a score ranging from 0 to 4, with 4 indicating highest level of performance and 0 indicating inability to complete test. A summary score ranging from 0 (worst performers) to 12 (best performers) is calculated by adding walking speed, chair stands and balance scores.

From baseline to post-operative visit (approximately week 9)
Change in Muscle Strength from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

The 1RM (repetition maximum) will be estimated from 10RM muscle strength tests on two exercises: 1) leg press, 2) chest press. 1RM values will be calculated and reported using validated equations.

From baseline to post-operative visit (approximately week 9)
Change in Height from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

Height will be measured using a stadiometer, rounding up to the nearest 0.1 cm

From baseline to post-operative visit (approximately week 9)
Change in Weight from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

Assessed by weight, rounding up to the nearest 0.1 kg.

From baseline to post-operative visit (approximately week 9)
Change in Waist Circumference from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

Waist circumference will be measured, rounding up to the nearest 0.1cm.

From baseline to post-operative visit (approximately week 9)
Change in Hip Circumference from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

Hip circumference will be measured, rounding up to the nearest 0.1cm.

From baseline to post-operative visit (approximately week 9)
Change in Body Mass Index from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)

Body composition will be assessed via bioelectrical impedance using a validated device. The device will estimate body fat using an algorithm based on participant age, sex, height, and body weight.

From baseline to post-operative visit (approximately week 9)
Change in Nutritional Status from Baseline to Post-Surgery (Group A)
時間枠:From baseline to postoperative visit, up to 9 weeks

Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level.

From baseline to postoperative visit, up to 9 weeks
Change in Nutritional Status from Baseline to Post-Surgery (Group B)
時間枠:From baseline to postoperative visit, up to 9 weeks

Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level.

From baseline to postoperative visit, up to 9 weeks
Change in Quality of Life from Baseline to Post-Surgery (Group A)
時間枠:From baseline to postoperative visit, up to 9 weeks

Assessed by the European Organization for Research and Treatment of Cancer's (EORTC's) Quality of Life (QOL) core questionnaire (QLQ C-30), a validated, 30-item instrument designed to quantify and measure QOL in cancer participants. Questions are rated on a four point scale from 1 "Not at all" to 4 "Very much. All items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life.

From baseline to postoperative visit, up to 9 weeks
Change in Quality of Life from Baseline to Post-Surgery (Group B)
時間枠:From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in Pittsburgh Sleep Quality Index (PSQI) Score from Baseline to Post-Surgery (Group A)
時間枠:From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in PSQI Score from Baseline to Post-Surgery (Group B)
時間枠:From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group A)
時間枠:From baseline to postoperative visit, up to 9 weeks

Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill).

From baseline to postoperative visit, up to 9 weeks
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group B)
時間枠:From baseline to postoperative visit, up to 9 weeks

Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill).

From baseline to postoperative visit, up to 9 weeks
Length of Hospitalization Post-Surgery (Group A)
時間枠:30 Days

Defined as the number of days of hospitalization post-surgery.

30 Days
Length of Hospitalization Post-Surgery (Group B)
時間枠:30 Days

Defined as the number of days of hospitalization post-surgery.

30 Days
Time To Return of Bowel Function Post-Surgery (Group A)
時間枠:30 Days

Defined as the number of days to a return of bowl function post-surgery.

30 Days
Time To Return of Bowel Function Post-Surgery (Group B)
時間枠:30 Days

Defined as the number of days to a return of bowl function post-surgery.

30 Days
Discharge Disposition (Group B)
時間枠:30 Days

Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics.

30 Days
Discharge Disposition (Group A)
時間枠:30 Days

Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics.

30 Days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Jeffrey Meyerhardt, MD, MPH、Dana-Farber Cancer Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月15日

一次修了 (推定)

2027年7月1日

研究の完了 (推定)

2027年12月30日

試験登録日

最初に提出

2024年8月16日

QC基準を満たした最初の提出物

2024年8月19日

最初の投稿 (実際)

2024年8月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共有時間枠

Data can be shared no earlier than 1 year following the date of publication

IPD 共有アクセス基準

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する